6. パーキンソン病 Parkinson disease Clinical trials / Disease details

臨床試験数 : 2,298 / 薬物数 : 2,202 - (DrugBank : 350) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 202

3 trials found

diseases per page:

Showing 1 to 3 of 3 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04575259 (ClinicalTrials.gov)	October 10, 2019	29/9/2020	OLE Study for Patients With Parkinson's Disease With Dementia Enrolled in Study ANAVEX2-73-PDD-001	Open Label Extension Study for Patients With Parkinson's Disease With Dementia Enrolled in Study ANA ...	Parkinson Disease Dementia	Drug: ANAVEX2-73	Anavex Life Sciences Corp.	Anavex Australia Pty Ltd.;Anavex Germany GmbH	Active, not recruiting	50 Years	85 Years	All	132	Phase 2	Australia;Spain
2	NCT03774459 (ClinicalTrials.gov)	July 9, 2018	8/12/2018	ANAVEX2-73 Study in Parkinson's Disease Dementia	A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, ...	Parkinsons Disease With Dementia	Drug: High dose ANAVEX2-73;Drug: Mid dose ANAVEX2-73;Drug: Placebo oral capsule	Anavex Life Sciences Corp.	Anavex Germany GmbH	Completed	50 Years	85 Years	All	132	Phase 2	Australia;Spain
3	EUCTR2017-004335-36-ES (EUCTR)	04/07/2018	11/04/2018	A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, ...	A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, ...	Cognition in Parkinson’s Disease with dementia;Therapeutic area: Diseases [C] - Nervous System Disea ...	Product Name: ANAVEX2-73 INN or Proposed INN: ANAVEX2-73 Product Name: ANAVEX2-73 INN or Proposed INN: ...	Anavex Life Sciences Corp.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	120	Phase 2	Spain

First Previous1Next Last